• Kryptowährungen
  • Prognosemärkte
  • Nachrichten
  • Agentic Trading
  • Artikel
  • Ligen

Suche Kryptowährungen

Trendende Kryptowährungen

CoinRithm

Firma

Rechtsträger
Bees-x Limited
Unternehmensnummer
13308136
Eingetragen in
England and Wales
Eingetragener Sitz
Monmouth House, High Street, Watford, England, WD17 1LN

CoinRithm ist ein Informations- und Recherchedienst der Bees-x Limited. Das Unternehmen ist von der Financial Conduct Authority (FCA) nicht zur Ausübung regulierter Tätigkeiten zugelassen, und nichts auf dieser Website stellt Finanzberatung dar.

Entdecken

KryptowährungenPrognosemärkteNachrichtenArtikelAgent ArenaLigen

Funktionen

DashboardProbespielAgentic TradingPortfolioBeobachtungslisteEinstellungen

Firma

Über UnsMethodikFür den UnterrichtNutzungsbedingungenDatenschutzrichtlinieCookie-RichtlinieHaftungsausschluss

Support

KundendienstFAQEntwickler-KitMCP-Dokumentation

Soziale Medien

X (Twitter)FacebookLinkedInTelegramInstagramTikTokYouTube
© 2026 CoinRithm. Alle Rechte vorbehalten.
Jetzt bei Google PlayLaden im App Store
  • Start
  • MärktePrognosemärkte
  • Nachrichten
  • Dashboard
  1. Prognosemärkte
  2. Regulierung
  3. FDA decision: DTX401 (pariglasgene brecaparvovec) by Ultragenyx Pharmaceutical (in 2026)
FDA decision: DTX401 (pariglasgene brecaparvovec) by Ultragenyx Pharmaceutical (in 2026)

FDA decision: DTX401 (pariglasgene brecaparvovec) by Ultragenyx Pharmaceutical (in 2026)

RegulierungOne-OffHealth & Medicine6Mon
KalshiKalshiVerfügbarkeit prüfenKYC erforderlich2% Gebühr
Aktuelle implizite Wahrscheinlichkeit
Ja
Ja 0%
Marktqualitat

24 / 100

Niedrige Qualität
24h-Volumen

0 €

Liquidität

0 €

Niedrige Liquidität
Geld / Brief

61.0% / 69.0%

Spread

13.1%

Breiter Spread
Marktdaten

Aktualisiert vor 3 Minuten

17. Juni 26, 21:001. Jan. 27, 4:59

Trends

Ergebnis24hWahrscheinlichkeit
Ja
Ja
0%
Nein
Nein
100%

Gewähltes Ergebnis

Yes0%

Regeln

If the FDA's decision on DTX401 (pariglasgene brecaparvovec) by Ultragenyx Pharmaceutical in 2026 is a full approval or an accelerated approval, the market resolves to Yes.

Kalshi
  • This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.
  • DTX401 (pariglasgene brecaparvovec) is a one-time gene therapy developed by Ultragenyx Pharmaceutical to treat Glycogen Storage Disease Type Ia (GSDIa), a rare inherited disorder in which the liver cannot properly release stored sugar into the bloodstream.
  • Think of it like installing a corrected instruction manual inside liver cells: after a single infusion, the therapy is designed to restore the missing enzyme activity — glucose-6-phosphatase — so the liver can once again regulate blood sugar on its own.
  • In the Phase 3 GlucoGene trial , DTX401 produced a statistically significant 41.3% mean reduction in daily cornstarch intake at Week 48 versus 10.3% for placebo (p<0.0001), with durability data at 96 weeks showing approximately 60–61% reductions.

Verwandte Märkte

Manifold Markets

Testosterone unscheduled/rescheduled more permissively in US by end of 2028?

994,7 €
Ja: 22.2%Manifold MarketsMANIFOLD MARKETS
Manifold Markets

Will China have more phase 3 drug trials than the United States in year X?

367,9 €
2026: 33%Manifold MarketsMANIFOLD MARKETS
Manifold Markets

Will estradiol be available over-the-counter in the US before 2030?

303 €
Ja: 8.2%Manifold MarketsMANIFOLD MARKETS
FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)

FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)

0 €
Ja: 0%KalshiKALSHI
Hantavirus pandemic in 2026?

Hantavirus pandemic in 2026?

38.193,4 €
Ja: 4%PolymarketPOLYMARKET
New pandemic in 2026?

New pandemic in 2026?

5220,5 €
Ja: 11%PolymarketPOLYMARKET

In diesen Themen aktiv

BitcoinBTC$64,565.28-1.93%EthereumETH$1,754.71-2.39%SolanaSOL$72.38-1.70%DogecoinDOGE$0.0862-1.45%XRPXRP$1.19-2.25%BNBBNB$602.70-0.56%

Verwandte Nachrichten

Binance MiCA License Application Cleared by Greek Regulator, June 30 Update AwaitedBlockchain ReporterCLARITY Act faces ethics showdown as David Nage eyes July voteCrypto NewsBinance EU Access at Risk as Greek Regulator Set to Reject MiCA License BidBlockchain ReporterSolana Institute warns Senate against weakening CLARITY ActCrypto NewsSummer of crypto (regs): State of Crypto CoindeskPhilippine Central Bank Bars VASPs From Listing Privacy CoinsBlockchain Reporter

Regeln

If the FDA's decision on DTX401 (pariglasgene brecaparvovec) by Ultragenyx Pharmaceutical in 2026 is a full approval or an accelerated approval, the market resolves to Yes.

Kalshi
  • This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.
  • DTX401 (pariglasgene brecaparvovec) is a one-time gene therapy developed by Ultragenyx Pharmaceutical to treat Glycogen Storage Disease Type Ia (GSDIa), a rare inherited disorder in which the liver cannot properly release stored sugar into the bloodstream.
  • Think of it like installing a corrected instruction manual inside liver cells: after a single infusion, the therapy is designed to restore the missing enzyme activity — glucose-6-phosphatase — so the liver can once again regulate blood sugar on its own.
  • In the Phase 3 GlucoGene trial , DTX401 produced a statistically significant 41.3% mean reduction in daily cornstarch intake at Week 48 versus 10.3% for placebo (p<0.0001), with durability data at 96 weeks showing approximately 60–61% reductions.